fluorouracil has been researched along with Foot Dermatoses in 62 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Foot Dermatoses: Skin diseases of the foot, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used." | 9.14 | A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 9.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine." | 9.14 | Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 9.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 9.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 9.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)." | 9.10 | Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 7.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 7.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| "Hand-foot syndrome is a common adverse effect of therapy with capecitabine (Xeloda) for the treatment of various carcinomas." | 7.76 | Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. ( Fraga, G; Gadzia, J; Latif, S, 2010) |
| "A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin." | 7.76 | High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010) |
| " The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy." | 7.75 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009) |
| "Hyperpigmentation of the hands and feet is a rare side effect with capecitabine chemotherapy and appeared to predict impending grade 2 HFS in our patients." | 7.74 | Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. ( Easaw, JC; Vickers, MM, 2008) |
| "A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine." | 7.74 | [Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 7.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 7.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "Capecitabine is a chemotherapeutic drug for use in cancers." | 5.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| "Capecitabine was developed as a prodrug of 5-fluorouracil (FU), with the goal of improving tolerability and intratumour drug concentrations through tumour-specific conversion to the active drug against numerous types of neoplasms." | 5.34 | Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? ( Do, JE; Kim, YC, 2007) |
| "Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon)." | 5.34 | [Capecitabine-induced hyperpigmentation]. ( Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C, 2007) |
| "Capecitabine was not resumed, and the rash resolved in 3 weeks with the use of pyridoxine and Udderly Smooth balm." | 5.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used." | 5.14 | A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009) |
| "To compare the efficacy and toxicity of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin (5-Fu/LV) plus oxaliplatin (FOLFOX4) regimens as adjuvant chemotherapy for stage III colorectal cancer." | 5.14 | [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. ( Fang, F; Li, DC; Lu, GC, 2010) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 5.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine." | 5.14 | Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010) |
| "Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis." | 5.14 | Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 5.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 5.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 5.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)." | 5.10 | Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003) |
| "Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil." | 4.87 | [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. ( Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A, 2011) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 3.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "A 60-year-old Ghanese woman was treated with radiotherapy and capecitabine for metastatic breast cancer." | 3.77 | [A woman with palmar and plantar hyperpigmentation]. ( van Tienhoven, G; Wilmink, JW, 2011) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 3.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| "Hand-foot syndrome is a common adverse effect of therapy with capecitabine (Xeloda) for the treatment of various carcinomas." | 3.76 | Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. ( Fraga, G; Gadzia, J; Latif, S, 2010) |
| "A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin." | 3.76 | High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010) |
| " The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy." | 3.75 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009) |
| "A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine." | 3.74 | [Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007) |
| "Hyperpigmentation of the hands and feet is a rare side effect with capecitabine chemotherapy and appeared to predict impending grade 2 HFS in our patients." | 3.74 | Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. ( Easaw, JC; Vickers, MM, 2008) |
| " This article presents the case of a 69-year-old African American man with a gastric adenocarcinoma status post gastrectomy who received 5-fluorouracil (5-FU) plus leucovorin for 5 days, to be followed by radiation plus capecitabine given 5 days per week for 5 weeks, and then 8 weeks of capecitabine monotherapy." | 3.74 | Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? ( Saif, MW; Sandoval, A, 2008) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 3.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 3.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "Capecitabine combined with fractionated cisplatin is highly effective and well tolerated as a first-line treatment for advanced gastric cancer, with comparable results to 5-Fu plus cisplatin combination therapy." | 2.73 | [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study]. ( Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y, 2008) |
| "Metastatic renal cell carcinoma (RCC) has modest response rates to chemotherapy with gemcitabine and 5-fluorouracil (5-FU)." | 2.71 | A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. ( Rini, BI; Small, EJ; Weinberg, V, 2005) |
| "Palmar-plantar erythrodysesthesia (PPE) or hand-foot syndrome (HFS) is a relatively common side effect of cytotoxic chemotherapy." | 2.44 | Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. ( Harrold, K; How, C; Webster-Gandy, JD, 2007) |
| " HFS is a leading cause of treatment interruption, dosage reduction, or, even, therapy discontinuation for patients on a capecitabine regimen." | 2.44 | Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? ( Goldberg, RM; McLeod, HL; Yen-Revollo, JL, 2008) |
| "Capecitabine is a chemotherapeutic drug for use in cancers." | 1.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| "Capecitabine was designed to generate 5FU via the thymidine phosphorylase (TP) enzyme, preferentially expressed in tumoral tissues." | 1.35 | Candidate mechanisms for capecitabine-related hand-foot syndrome. ( Etienne-Grimaldi, MC; Formento, JL; Francoual, M; Hofman, P; Lacour, JP; Lassalle, S; Mari, M; Milano, G, 2008) |
| "Capecitabine is a prodrug of fluorouracil." | 1.35 | Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine. ( Alonso, V; Calduch, L; Jordá, E; Martín, JM; Pinazo, MI; Villalón, G, 2009) |
| "Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome." | 1.35 | Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. ( Au, GK; Chua, D; Sham, JS; Wei, WI, 2008) |
| " Hand-foot syndrome (HFS) is a relatively common side effect of cytotoxic chemotherapy." | 1.35 | Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? ( Rajebi, MR; Saif, MW; Shahrokni, A, 2009) |
| "Capecitabine was developed as a prodrug of 5-fluorouracil (FU), with the goal of improving tolerability and intratumour drug concentrations through tumour-specific conversion to the active drug against numerous types of neoplasms." | 1.34 | Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? ( Do, JE; Kim, YC, 2007) |
| " HFS manifests as acral erythema, with swelling and dysesthesia of the palms and plantar aspects of the feet, which in the absence of dosage reduction or drug cessation, progresses to moist desquamation and ulceration, resulting in serious infections and loss of function." | 1.34 | Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. ( Hwang, SJ; Kim, BS; Kim, HJ; Kim, YJ; Lee, SD; Nam, SH, 2007) |
| "Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon)." | 1.34 | [Capecitabine-induced hyperpigmentation]. ( Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C, 2007) |
| "Capecitabine was not resumed, and the rash resolved in 3 weeks with the use of pyridoxine and Udderly Smooth balm." | 1.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "5-Fluorouracil (5-FU) is an antimetabolite frequently used in the treatment of cancer." | 1.29 | Dermatological toxicity from chemotherapy containing 5-fluorouracil. ( Campanella, GA; Carrieri, G; Colucci, G; Leo, S; Tatulli, C; Taveri, R, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (16.13) | 18.7374 |
| 1990's | 4 (6.45) | 18.2507 |
| 2000's | 34 (54.84) | 29.6817 |
| 2010's | 14 (22.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lacouture, ME | 1 |
| Reilly, LM | 1 |
| Gerami, P | 1 |
| Guitart, J | 1 |
| Saif, MW | 4 |
| Sandoval, A | 1 |
| Hénin, E | 1 |
| You, B | 1 |
| VanCutsem, E | 1 |
| Hoff, PM | 1 |
| Cassidy, J | 1 |
| Twelves, C | 1 |
| Zuideveld, KP | 1 |
| Sirzen, F | 1 |
| Dartois, C | 1 |
| Freyer, G | 1 |
| Tod, M | 1 |
| Girard, P | 1 |
| Hu, B | 1 |
| Yu, JR | 1 |
| Wen, ZZ | 1 |
| Shu, YQ | 1 |
| Wang, BC | 1 |
| Yin, HR | 1 |
| Chen, L | 2 |
| Bai, YX | 1 |
| Liang, J | 1 |
| Cheng, Y | 1 |
| Shen, L | 1 |
| Zhou, Y | 1 |
| Zhang, HG | 1 |
| Li, J | 1 |
| Wan, DS | 2 |
| Chen, S | 1 |
| Jia, TZ | 1 |
| Jin, ML | 1 |
| Vickers, MM | 1 |
| Easaw, JC | 1 |
| Villalón, G | 1 |
| Martín, JM | 1 |
| Pinazo, MI | 1 |
| Calduch, L | 1 |
| Alonso, V | 1 |
| Jordá, E | 1 |
| Yoshimoto, N | 1 |
| Yamashita, T | 1 |
| Fujita, T | 1 |
| Hayashi, H | 1 |
| Tsunoda, N | 1 |
| Kimura, M | 1 |
| Tsuzuki, N | 1 |
| Yamashita, H | 1 |
| Toyama, T | 1 |
| Kondo, N | 1 |
| Iwata, H | 1 |
| Shahrokni, A | 1 |
| Rajebi, MR | 1 |
| Son, HS | 1 |
| Lee, WY | 1 |
| Lee, WS | 1 |
| Yun, SH | 1 |
| Chun, HK | 1 |
| Latif, S | 1 |
| Fraga, G | 1 |
| Gadzia, J | 1 |
| Lu, GC | 1 |
| Fang, F | 1 |
| Li, DC | 1 |
| Taguchi, T | 1 |
| Nakayama, T | 1 |
| Masuda, N | 1 |
| Yoshidome, K | 1 |
| Akagi, K | 1 |
| Nishida, Y | 1 |
| Yoshikawa, Y | 1 |
| Ogino, N | 1 |
| Abe, C | 1 |
| Sakamoto, J | 2 |
| Noguchi, S | 1 |
| Kang, YK | 1 |
| Lee, SS | 1 |
| Yoon, DH | 1 |
| Lee, SY | 1 |
| Chun, YJ | 1 |
| Kim, MS | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Lee, JL | 1 |
| Kim, TW | 1 |
| Kamil, M | 1 |
| Haron, M | 1 |
| Yosuff, N | 1 |
| Khalid, I | 1 |
| Azman, N | 1 |
| Chalermchai, T | 1 |
| Tantiphlachiva, K | 1 |
| Suwanrusme, H | 1 |
| Voravud, N | 1 |
| Sriuranpong, V | 1 |
| Wolf, SL | 1 |
| Qin, R | 1 |
| Menon, SP | 1 |
| Rowland, KM | 1 |
| Thomas, S | 1 |
| Delaune, R | 1 |
| Christian, D | 1 |
| Pajon, ER | 1 |
| Satele, DV | 1 |
| Berenberg, JL | 1 |
| Loprinzi, CL | 1 |
| Zhang, RX | 1 |
| Wu, XJ | 1 |
| Lu, SX | 1 |
| Pan, ZZ | 1 |
| Chen, G | 1 |
| Caronia, D | 1 |
| Martin, M | 1 |
| Sastre, J | 1 |
| de la Torre, J | 1 |
| García-Sáenz, JA | 1 |
| Alonso, MR | 1 |
| Moreno, LT | 1 |
| Pita, G | 1 |
| Díaz-Rubio, E | 1 |
| Benítez, J | 1 |
| González-Neira, A | 1 |
| Bartal, A | 1 |
| Mátrai, Z | 1 |
| Szûcs, A | 1 |
| Liszkay, G | 1 |
| van Tienhoven, G | 1 |
| Wilmink, JW | 1 |
| Ciccolini, J | 2 |
| Evrard, A | 1 |
| Lacarelle, B | 1 |
| Piguet, V | 1 |
| Borradori, L | 1 |
| Moehler, M | 1 |
| Gutzler, F | 1 |
| Steinmann, S | 1 |
| Boehme, M | 1 |
| Raeth, U | 1 |
| Stremmel, W | 1 |
| Galle, PR | 1 |
| Rudi, J | 1 |
| Risum, S | 1 |
| Langer, SW | 1 |
| Park, YH | 1 |
| Ryoo, BY | 1 |
| Lee, HJ | 1 |
| Kim, SA | 1 |
| Chung, JH | 1 |
| Takahashi, K | 1 |
| Mori, T | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, H | 1 |
| Miyamoto, H | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Katayanagi, S | 1 |
| Danby, W | 1 |
| Kondo, Y | 1 |
| Takemiya, S | 1 |
| Sakamoto, N | 1 |
| Nishisho, I | 1 |
| Sorscher, SM | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Etienne-Grimaldi, MC | 2 |
| Milano, G | 2 |
| Rini, BI | 1 |
| Weinberg, V | 1 |
| Small, EJ | 1 |
| Gugerli, O | 1 |
| Leupin, N | 1 |
| Marini, A | 1 |
| Hengge, UR | 1 |
| Elfiky, A | 1 |
| Diasio, R | 1 |
| Webster-Gandy, JD | 1 |
| How, C | 1 |
| Harrold, K | 1 |
| Do, JE | 1 |
| Kim, YC | 1 |
| Lee, SD | 1 |
| Kim, HJ | 1 |
| Hwang, SJ | 1 |
| Kim, YJ | 1 |
| Nam, SH | 1 |
| Kim, BS | 1 |
| Shimomatsuya, T | 1 |
| Mitsudou, Y | 1 |
| Nakamura, T | 1 |
| Yonezawa, K | 1 |
| Shiraishi, S | 1 |
| Fujino, M | 1 |
| Maruhashi, K | 1 |
| Vázquez-Bayo, C | 1 |
| Rodríguez-Bujaldón, AL | 1 |
| Jiménez-Puya, R | 1 |
| Galán-Gutiérrez, M | 1 |
| Moreno-Giménez, JC | 1 |
| Kern, E | 1 |
| Schmidinger, M | 1 |
| Locker, GJ | 1 |
| Kopp, B | 1 |
| Yucel, I | 1 |
| Guzin, G | 1 |
| Tavares-Bello, R | 1 |
| Weiss, E | 1 |
| Amini, S | 1 |
| Yen-Revollo, JL | 1 |
| Goldberg, RM | 1 |
| McLeod, HL | 1 |
| Mari, M | 1 |
| Lassalle, S | 1 |
| Formento, JL | 1 |
| Francoual, M | 1 |
| Lacour, JP | 1 |
| Hofman, P | 1 |
| Traina, TA | 1 |
| Theodoulou, M | 1 |
| Feigin, K | 1 |
| Patil, S | 1 |
| Tan, KL | 1 |
| Edwards, C | 1 |
| Dugan, U | 1 |
| Norton, L | 1 |
| Hudis, C | 1 |
| Chua, D | 1 |
| Wei, WI | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| McCarthy, DJ | 1 |
| Berlin, SJ | 1 |
| Leo, S | 1 |
| Tatulli, C | 1 |
| Taveri, R | 1 |
| Campanella, GA | 1 |
| Carrieri, G | 1 |
| Colucci, G | 1 |
| Chiara, S | 1 |
| Nobile, MT | 1 |
| Barzacchi, C | 1 |
| Sanguineti, O | 1 |
| Vincenti, M | 1 |
| Di Somma, C | 1 |
| Meszaros, P | 1 |
| Rosso, R | 1 |
| Langer, K | 1 |
| Zonzits, E | 1 |
| Konrad, K | 1 |
| Fabian, CJ | 1 |
| Molina, R | 1 |
| Slavik, M | 1 |
| Dahlberg, S | 1 |
| Giri, S | 1 |
| Stephens, R | 1 |
| Dockery, GL | 1 |
| Nilson, RZ | 1 |
| Curran, CF | 1 |
| Luce, JK | 1 |
| Feldman, LD | 1 |
| Ajani, JA | 1 |
| Swain, R | 1 |
| Guillaume, JC | 1 |
| Carp, E | 1 |
| Rougier, P | 1 |
| Charpentier, P | 1 |
| André, P | 1 |
| Carde, P | 1 |
| Avril, MF | 1 |
| Caballero, GA | 1 |
| Ausman, RK | 1 |
| Quebbeman, EJ | 1 |
| Atkins, JN | 1 |
| Bunney, MH | 1 |
| Guss, SB | 1 |
| Osbourn, RA | 1 |
| Lutzner, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind Phase III Study of Pyridoxine vs Placebo for the Prevention of Capecitabine-induced Hand-Foot Syndrome[NCT00446147] | Phase 3 | 389 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036] | Phase 3 | 137 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| "Evaluation of the Restorative Efficacy of the Cosmetic Product Onco-Repair vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo."[NCT03612011] | Phase 3 | 72 participants (Actual) | Interventional | 2018-07-12 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A total administered dose of capecitabine until the development of grade 2 or higher hand-foot syndrome during the chemotherapy. (NCT00446147)
Timeframe: Up to 2 years
| Intervention | miligram per square meter (Median) |
|---|---|
| Placebo | 70000 |
| Pyridoxine | 70000 |
Number of patients with any grade of hand-foot syndrome (NCT00446147)
Timeframe: Up to 2 years
| Intervention | participants (Number) |
|---|---|
| Placebo | 55 |
| Pyridoxine | 57 |
A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Urea/Lactic Acid Cream | 13.6 |
| Placebo Cream | 10.2 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Placebo Cream | 18 | 3 |
| Urea/Lactic Acid Cream | 21 | 3 |
4 reviews available for fluorouracil and Foot Dermatoses
| Article | Year |
|---|---|
Capecitabine and hand-foot syndrome.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diagnos | 2011 |
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Topics: Antineoplastic Agents; Capecitabine; Cytarabine; Deoxycytidine; Docetaxel; Doxorubicin; Fluorouracil | 2011 |
Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Topics: Activities of Daily Living; Antineoplastic Agents; Cancer Care Facilities; Cryotherapy; Cytarabine; | 2007 |
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Enzyme Inhibitors; Fluorouracil; Foot Der | 2008 |
12 trials available for fluorouracil and Foot Dermatoses
| Article | Year |
|---|---|
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluoroura | 2009 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2010 |
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2003 |
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progre | 2004 |
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2005 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
46 other studies available for fluorouracil and Foot Dermatoses
| Article | Year |
|---|---|
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2008 |
Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Black or African American; Capecitabine; Deox | 2008 |
Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouraci | 2008 |
Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermoscopy; Female; | 2009 |
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2010 |
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2009 |
Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasm | 2009 |
Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Count; Deoxycytidine; Female; Fluorouracil | 2010 |
High frequency of hand foot syndrome with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cross-Sectional St | 2010 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breas | 2011 |
[A woman with palmar and plantar hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil | 2011 |
A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Erythema; Female; Fluorouracil; | 2012 |
Pyogenic granuloma-like lesions during capecitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Fluorouracil; Fo | 2002 |
[Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response R | 2003 |
High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluo | 2003 |
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 2003 |
Treatment of porokeratosis with fluorouracil and salicylic acid under occlusion.
Topics: Administration, Cutaneous; Drug Therapy, Combination; Fluorouracil; Foot Dermatoses; Humans; Male; M | 2003 |
Penile involvement with hand-foot syndrome.
Topics: Antineoplastic Agents; Drug Eruptions; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; | 2004 |
Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Topics: Antineoplastic Agents; beta-Alanine; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Dose-Resp | 2004 |
[Blisters unlike others].
Topics: Aged; Antimetabolites, Antineoplastic; Blister; Capecitabine; Deoxycytidine; Drug Eruptions; Female; | 2006 |
[Hand-foot syndrome with capecitabine therapy].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neopl | 2007 |
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycyt | 2006 |
Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; F | 2007 |
Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorourac | 2007 |
[A case of severe hand-foot syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration | 2007 |
[Capecitabine-induced hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; F | 2007 |
[Management of capecitabine-induced hand-foot syndrome by local phytotherapy].
Topics: Antimetabolites, Antineoplastic; Calendula; Capecitabine; Deoxycytidine; Fluorouracil; Foot Dermatos | 2007 |
Topical henna for capecitabine induced hand-foot syndrome.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine | 2008 |
Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; | 2007 |
A novel treatment for knuckle pads with intralesional Fluorouracil.
Topics: Adult; Antimetabolites; Female; Finger Joint; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans | 2007 |
Candidate mechanisms for capecitabine-related hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Cell Proliferation; Deoxycytidine; Fem | 2008 |
Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease-Free Survival; Dr | 2008 |
The ultrastructural effects of 5-fluorouracil in the management of pedal verrucae.
Topics: Female; Fluorouracil; Foot Dermatoses; Humans; Male; Skin; Warts | 1982 |
Dermatological toxicity from chemotherapy containing 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1994 |
Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Hyperkeratosis lenticularis perstans (Flegel's disease). Ultrastructural study of lesional and perilesional skin and therapeutic trial of topical tretinoin versus 5-fluorouracil.
Topics: Administration, Cutaneous; Fluorouracil; Foot Dermatoses; Humans; Keratosis; Leg Dermatoses; Male; M | 1992 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Topics: Colonic Neoplasms; Edema; Erythema; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatose | 1990 |
Intralesional injections.
Topics: Adrenal Cortex Hormones; Bleomycin; Fluorouracil; Foot Dermatoses; Foot Diseases; Humans; Hyaluronog | 1986 |
Fluorouracil and palmar-plantar erythrodysesthesia.
Topics: Erythema; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Pain | 1989 |
Fluorouracil-associated dermatitis of the hands and feet.
Topics: Adult; Drug Eruptions; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male | 1985 |
Topical 5-fluorouracil for corns--an effective new treatment.
Topics: Callosities; Fluorouracil; Foot Dermatoses; Humans; Toes | 1986 |
[Cutaneomucous adverse effects of continuous infusion of 5-fluorouracil: 12 cases].
Topics: Adult; Drug Eruptions; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Infusions, In | 1988 |
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil | 1985 |
Fluorouracil and the palmar-plantar erythrodysesthesia syndrome.
Topics: Dermatitis, Exfoliative; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged | 1985 |
The treatment of plantar warts with 5-fluorouracil.
Topics: Fluorouracil; Foot Dermatoses; Humans; Occlusive Dressings; Warts | 1973 |
Porokeratosis plantaris, palmaris, et disseminata. A third type of porokeratosis.
Topics: Adolescent; Adult; Age Factors; Aged; Biopsy; Carcinoma, Squamous Cell; Child; Female; Fluorouracil; | 1971 |